Observational study finds worse survival and lower immunotherapy access for melanoma patients in minority-serving hospitals, indicating healthcare disparities.
Stage IV melanoma patients treated at MSH were less likely to receive immunotherapy and had worse survival. These findings highlight institutional disparities beyond patient-level disadvantage and the need for interventions to strengthen access to life-prolonging therapies at MSH.
No takes yet. Share an insight, caveat, or question.
Mayhew et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: